RESEARCH ARTICLE

Prediction of various blood group systems using Korean whole-genome sequencing data

Jungwon Hyun¹, Sujin Oh², Yun Ji Hong^{2,3®}*, Kyoung Un Park^{2,3®}*

1 Department of Laboratory Medicine, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, South Korea, 2 Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, South Korea, 3 Department of Laboratory Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea

• These authors contributed equally to this work.

* aeiea@snu.ac.kr (YJH); m91w95pf@snu.ac.kr (KUP)

Abstract

Aims

This study established blood group analysis methods using whole-genome sequencing (WGS) data and conducted blood group analyses to determine the domestic allele frequency using public data from the Korean whole sequence analysis of the Korean Reference Genome Project conducted by the Korea Disease Control and Prevention Agency (KDCA).

Materials and methods

We analyzed the differences between the human reference sequences (hg19) and the conventional reference cDNA sequences of blood group genes using the Clustal Omega website, and established blood group analysis methods using WGS data for 41 genes, including 39 blood group genes involved in 36 blood group antigens, as well as the *GATA1* and *KLF1* genes, which are erythrocyte-specific transcription factor genes. Using CLC genomics Workbench 11.0 (Qiagen, Aarhus, Denmark), variant analysis was performed on these 41 genes in 250 Korean WGS data sets, and each blood group's genotype was predicted. The frequencies for major alleles were also investigated and compared with data from the Korean rare blood program (KRBP) and the Erythrogene database (East Asian and all races).

Results

Among the 41 blood group-related genes, hg19 showed variants in the following genes compared to the conventional reference cDNA: *GYPA*, *RHD*, *RHCE*, *FUT3*, *ACKR1*, *SLC14A1*, *ART4*, *CR1*, and *GCNT2*. Among 250 WGS data sets from the Korean Reference Genome Project, 70.6 variants were analyzed in 205 samples; 45 data samples were excluded due to having no variants. In particular, the *FUT3*, *GNCT2*, *B3GALNT1*, *CR1*, and *ACHE* genes contained numerous variants, with averages of 21.1, 13.9, 13.4, 9.6, and 7.0, respectively. Except for some blood groups, such as ABO and Lewis, for which it was difficult to predict the alleles using only WGS data, most alleles were successfully predicted in most blood



GOPEN ACCESS

Citation: Hyun J, Oh S, Hong YJ, Park KU (2022) Prediction of various blood group systems using Korean whole-genome sequencing data. PLoS ONE 17(6): e0269481. https://doi.org/10.1371/journal. pone.0269481

Editor: Ahmet Emre Eşkazan, İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, TURKEY

Received: December 6, 2021

Accepted: May 20, 2022

Published: June 3, 2022

Copyright: © 2022 Hyun et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: The authors received no specific funding for this work.

Competing interests: The authors have declared that no competing interests exist.

groups. A comparison of allele frequencies showed no significant differences compared to the KRBP data, but there were differences compared to the Erythrogene data for the Lutheran, Kell, Duffy, Yt, Scianna, Landsteiner-Wiener, and Cromer blood group systems. Numerous minor blood group systems that were not available in the KRBP data were also included in this study.

Conclusions

We successfully established and performed blood group analysis using Korean public WGS data. It is expected that blood group analysis using WGS data will be performed more frequently in the future and will contribute to domestic data on blood group allele frequency and eventually the supply of safe blood products.

Introduction

Human red blood cells contain many blood group antigens. To date, 43 blood group systems containing 345 red cell antigens have been officially recognized by the International Society of Blood Transfusion (ISBT) [1]. The diversity of blood group antigens is primarily due to single nucleotide polymorphisms (SNP) in blood group genes. Blood group antigen typing is classically conducted using serological testing by hemagglutination, but recently this process has been automated. DNA-based molecular diagnostics (genotyping) have replaced serological methods. That is, SNP-based molecular testing and Sanger sequencing are used to analyze specific SNPs, alongside DNA microarray methods in clinical laboratories [2-4]. Molecular testing is easy to automate, can be multiplexed, and does not require expensive and difficult-tofind antisera, making it possible to test a broader range of blood types for patients and donors, and to help identify donors and select blood products for rare blood types [5]. However, SNPbased molecular diagnosis or Sanger sequencing have limitations as they cannot include all known blood group genes or detect new blood group antigen alleles. Several commercial multiplexed molecular diagnostic kits are currently available, but they do not cover all known blood group genes, and at most, they only identify 35–37 of red blood cell antigens from 10–11 blood groups. Erythrocyte genotyping using next-generation sequencing (NGS) has several advantages [6-8]. NGS enables the evaluation of whole-genome sequences to detect gene rearrangements and analyze copy numbers. NGS can detect new alleles in addition to known SNPs and establish new weak or silencing alleles. One study performed blood group analysis using NGS data from 2,504 people provided by the 1000 Genomes Project, but Korean data were not included [9].

The Korean rare blood program (KRBP), known as the Korean national recipient registry, was established in July 2013 [10, 11]. The definition of a rare blood group depends on the prevalence of blood antigens in a specific population. Accurate data on the frequencies of various blood antigens are essential for a rare blood program, which can then be used to predict the availability of blood products for use in patients with the corresponding antibodies. We used commercially available multiplex molecular assays to establish the rare donor program and explored the prevalence of various blood group antigens. However, not all known blood group antigens were included. The present study established blood group analysis methods using whole-genome sequencing (WGS) data and conducted blood group analyses to determine the domestic allele frequencies. These were compared with previous KRBP data and data from other ethnic groups using public data from the Korean whole-genome sequencing analysis of

the Korean Reference Genome Project conducted by the Korea Disease Control and Prevention Agency (KDCA).

Materials and methods

Difference analysis between human reference sequences (hg19) and conventional reference cDNA

Conventional reference alleles and coding DNA sequences (CDS) were investigated for 41 genes (Table 1 and S1 Table), including 39 blood group genes involved in 36 blood group antigens, and the *GATA1* and *KLF1* genes, which are erythrocyte-specific transcription factor genes [12–14]. The conventional reference alleles for 40 genes were available directly from ISBT and *FUT3* alleles were available from the Blood Group Antigen Gene Mutation Database (dbRBC). The human reference genome (hg19) UCSC genomic transcripts (corresponding to the splicing pattern of the conventional cDNA sequence) for these 41 genes were also investigated using the UCSC genome browser [15]. The CDS of the conventional reference alleles and the human reference genomes for each gene were aligned, and the Clustal Omega website was used to identify nucleotide changes [16].We then analyzed the differences between hg19 and conventional reference cDNA and determined the blood group alleles of hg19 (Table 1). We described our overall work flow in S1 Fig.

Establishment of blood group analysis methods using WGS data

After importing the WGS data (BAM file) using CLC genomics Workbench 11.0 (Qiagen, Aarhus, Denmark) [17], the data were realigned to hg19, and variant analysis was performed on the coding regions of the 41 blood group-related genes. The alleles of each blood group were predicted by analyzing the variants for each gene and comparing them with the hg19 genotype.

Blood group analysis using Korean WGS public data

We received the 250 Korean WGS data (BAM files) of the Korean Reference Genome Project through the Human Resource Distribution Desk of the National Institute of Health of the KDCA. Variant analysis was performed on 41 blood group-related genes in the Korean WGS data using the above method, and the alleles of each blood group were predicted. The frequencies of the major alleles were also investigated and compared with the frequencies in the previous KRBP data and the Erythrogene database (East Asians and all races) using data from 2,504 people from 26 races of the 1000 Genomes Project.

Statistical analysis

Chi-square test and Fisher's exact test were applied to compare the allele frequencies and data with *P* values <0.05 were considered statistically significant. Statistical analyses were performed using MedCalc software, version 19.8 (MedCalc Software Ltd., Ostend, Belgium)

Ethics statement

This study uses public data, and since it uses already anonymized data, it does not contact the research subjects, uses information that has already been disclosed to the public and it was NGS data (BAM file) that did not include other medical records. This study was approved by the Institutional Ethics Committee of Seoul National University Bundang Hospital with waiver of consent and review exemption (IRB No. X-1801-447-906 and X-1903-528-901).

ISBT No.	System name (symbol)	Gene name	Chromosomal location	Conventional reference allele	Conventional reference phenotype	Nucleotide change	Predicted amino acid change	Predicted allele name
001	ABO (ABO)	ABO	9q34.2	ABO*A1.01	A ₁	-	-	ABO*A1.01
002	MNS (MNS)	GYPA	4q31.21	GYPA*01	MNS:1 or M+	38C>A; 59C>T; 71G>A; 72T>G; 93C>T	Ala13Glu; Ser20Leu; Gly24Glu	ND
		GYPB		GYPB*04	MNS:4 or s+	-	-	GYPB*04
003	P1PK (P1PK)	A4GALT	22q13.2	A4GALT*01	P1+/-, Pk+	-	-	A4GALT*01
004	Rh (RH)	RHD	1p36.11	RHD*01	D RH:1	1136C>T	Thr379Met	RHD* 10.00 RHD* DAU0
		RHCE		RHCE*01	RH:4 or c	48G>C	Trp16Cys	RHCE*01.01
					RH:5 or e			
					RH:6 or f (ce)			
005	Lutheran (LU)	BCAM	19q13.32	LU*02	LU:2 or Lu(b+)	-	-	LU*02
006	Kell (KEL)	KEL	7q34	KEL*02	KEL:2 or k+	-	-	KEL*02
007	Lewis (LE)	FUT3	19p13.3	FUT3	ND	202T>C; 314C>T	Trp68Arg; Thr105Met	FUT3 202C, 314T
008	Duffy (FY)	ACKR1	1q23.2	FY*02	FY:2 or Fy(b+)	125A>G	Asp42Gly	FY*01
009	Kidd (JK)	SLC14A1	18q12.3	JK*02	JK:2 or Jk(b+)	838A>G	Asn280Asp	JK*01
010	Diego (DI)	SLC4A1	17q21.31	DI*02	DI:-1,2 or Di(a-b+)	-	-	DI*02
011	Yt (YT)	ACHE	7q22.1	YT*01	YT:1 or Yt(a+)	-	-	YT*01
012	Xg (XG)	XG	Xp22.33	XG*01	Xg(a+)	-	-	XG*01
013	Scianna (SC)	ERMAP	1p34.2	SC*01	SC:1 or Sc1+	-	-	SC*01
014	Dombrock (DO)	ART4	12p12.3	DO*01	DO:1+ or Do(a+)	378C>T; 624T>C; 793A>G	Asn265Asp	DO*02
015	Colton (CO)	AQP1	7p14.3	CO*01.01	CO:1 or Co(a+)	-	-	CO*01.01
016	Landsteiner- Wiener (LW)	ICAM4	19p13.2	LW*05	LW:5 or LW(a+)	-	-	LW*05
017	Chido/ Rodgers (CH/RG)	C4A	6p21.33	C4A*3	Ch-Rg+	-	-	C4A*3
		C4B		C4B* 3	Ch+Rg-	_	_	C4B* 3
					CH/RG:1,2,3,4,5,6,- 11,-12			010 0
018	H (H)	FUT1	19q13.33	FUT1*01	H+	-	-	FUT1*01
		FUT2	-	FUT2*01	H+	-	-	FUT2*01
019	Kx (KX)	XK	Xp21.1	XK*01	XK:1 or Kx+	-	-	XK*01
020	Gerbich (GE)	GYPC	2q14.3	GE*01	GE:2,3,4	-	-	GE*01
021	Cromer (CROM)	CD55	1q32.2	CROM*01	CROM:1 or Cr(a+)	-	-	CROM*01
022	Knops (KN)	CR1	1q32.2	KN*01	KN:1, KN:3, KN:4, KN:8, KN:9	180G>A; 4828T>A; 5905G>A	Ser1610Thr; Ala1969Thr	ND
023	Indian (IN)	CD44	11p13	IN*02	In(a-b+)	-	-	IN*02
024	Ok (OK)	BSG	19p13.3	OK*01.01	OK:1 or Ok(a+)	-	-	OK*01.01
025	Raph (RAPH)	CD151	11p15.5	RAPH*01	RAPH:1 or MER2+	-	-	RAPH*01
026	John Milton Hagen (JMH)	SEMA7A	15q24.1	JMH*01	JMH:1 or JMH+	-	-	JMH*01
027	I (I)	GCNT2	6p24.3-p24.2	GCNT2*01	I	816G>C	Glu272Asp	GCNT2*02
028	Globoside (GLOB)	B3GALNT1	3q26.1	GLOB*01	GLOB:1 (P+)	-	-	GLOB*01
029	Gill (GIL)	AQP3	9p13.3	GIL*01	GIL:1 or GIL+	-	-	GIL*01

Table 1. Prediction of various blood group systems of human reference genome (hg19) compared to conventional cDNA sequences analyzed using Clustal Omega.

(Continued)

ISBT No.	System name (symbol)	Gene name	Chromosomal location	Conventional reference allele	Conventional reference phenotype	Nucleotide change	Predicted amino acid change	Predicted allele name
030	Rh-associated glycoprotein (RHAG)	RHAG	6p12.3	RHAG*01	RHAG:1 or Duclos+	-	-	RHAG*01
031	FORS (FORS)	GBGT1	9q34.2	GBGT1*01N.01	FORS:-1 (FORS-)	-	-	GBGT1*01N.01
032	JR (JR)	ABCG2	4q22.1	ABCG2*01	Jr(a+)	-	-	ABCG2*01
033	LAN (LAN)	ABCB6	2q35	ABCB6*01	Lan+	-	-	ABCB6*01
034	Vel (VEL)	SMIM1	1p36.32	VEL*01	Vel+	-	-	VEL*01
035	CD59 (CD59)	CD59	11p13	CD59*01	CD59:+1 or CD59.1 +	-	-	CD59*01
036	Augustine (AUG)	SLC29A1	6p21.1	AUG*01	At(a+) AUG:1	-	-	AUG*01
Associated genes		GATA1	Xp11.23	GATA1*01		-	-	GATA1*01
Associated genes		KLF1	19p13.13	KLF1*01		-	-	KLF1*01

Table 1. (Continued)

ISBT, International Society of Blood Transfusion; ND, not determined

https://doi.org/10.1371/journal.pone.0269481.t001

Results

Difference between hg19 and conventional reference cDNA

We investigated and analyzed the differences between the human reference sequences (hg19) and the CDS of the conventional reference alleles for 41 blood group-related genes. Table 1 lists the ISBT number, blood system name and symbol, gene name, chromosomal location, conventional reference allele, and phenotype for the 41 blood group-related genes analyzed in this study. Table 1 also lists the differences between hg19 and conventional cDNA for these 41 genes, including nucleotide changes, predicted amino acid changes, predicted allele name, and predicted phenotype. Among these 41 genes, hg19 showed variants in the following genes compared to the conventional reference cDNA: *GYPA*, *RHD*, *RHCE*, *FUT3*, *ACKR1*, *SLC14A1*, *ART4*, *CR1*, and *GCNT2*.

The conventional reference sequence for *GYPA**01 encodes an M+ phenotype. The human reference genome *GYPA* sequence showsc.38C>A[p.Ala13Glu] and c.93C>T[p.Thr31Thr] variants in addition to the *GYPA**02 allele encoding the N+ phenotype.

The *RHD* gene shows the c.1136C>T[p.Thr379Met] variant compared to the *RHD**01 conventional reference allele, which corresponds to the *RHD**DAU0 allele. *RHCE**01, the conventional reference allele of the *RHCE* gene, shows a c+e+ phenotype. However, the human reference genome shows the c.48G>C[p.Trp16Cys] variant, which corresponds to the *RHCE**01.01 allele encoding a weak e phenotype.

Compared to the conventional reference allele, the *FUT3* gene shows the c.202T>C[p. Trp68Arg] and c.314C>T[p.Thr105Met] variants, and these variants encode the Le(a-b-) phenotype.

The *ACKR1* gene shows a variant in c.125A>G[p.Asp42Gly] compared to the FY^*02 conventional reference allele encoding the Fy(b+) phenotype, corresponding to the FY^*01 allele showing the Fy(a+) phenotype.

The *SCL14A1* gene shows a c.838A>G[p.Asn280 Asp] variant compared to the *JK**02 conventional reference allele encoding the Jk(b+) phenotype, corresponding to the *JK**01 allele showing the Jk(a+) phenotype.

Compared to the DO^*01 conventional reference allele, which shows the Do(a+) phenotype, the *ART4* gene shows c.378C>T[p.Tyr126Tyr], c.624T>C[p.Leu208Leu], and c.793A>G[p. Asn265Asp] variants, which correspond to the DO^*02 allele showing the Do(b+) phenotype.

Compared to the conventional reference allele, the *CR1* gene shows the c.180G>A, c.4828T>A[p.Ser1610Thr], and c.5905G>A[p.Ala1969Thr] variants. The c.4828T>A[p. Ser1610Thr] variant encodes a high-frequency Knops antigen (SI3) deficiency and exhibits a SI3-(SI:1,-2,-3) phenotype (KN:-8).

Compared to the conventional reference allele, the *GCNT2* gene shows a c.816G>C [p. Glu272Asp] variant, which corresponds to the *GCNT2**02 allele and exhibits an I+ phenotype like *GCNT2**01, the conventional reference allele.

Blood group analysis using Korean WGS public data

Among the 250 WGS data sets of the Korean Reference Genome Project, an average of 70.6 variants were analyzed in 205 data samples. We excluded 45 data samples due to their showing no variants. The *FUT3*, *GNCT2*, *B3GALNT1*, *CR1*, and *ACHE* genes showed several variants, having an average of 21.1, 13.9, 13.4, 9.6, and 7.0 variants, respectively, making allele prediction for these genes difficult.

Other alleles were successfully predicted in most blood groups, except for ABO and Lewis, for which it was difficult to predict alleles and phenotypes from the WGS data alone. Table 2 lists the blood group system predictions from the representative data compared to conventional cDNA sequences.

Table 3 and Fig 1 show the allele frequencies compared with previous KRBP data sets and the Erythrogene (East Asian and all races) database. Allele frequencies were similar for the Lutheran, Kell, Duffy (FY^*01), Yt, Landsteiner-Wiener, and Cromer blood group systems compared to the KRBP data, but there were differences compared to the Erythrogene data. This study included numerous minor blood group systems that were not available in the KRBP data, and most showed allele frequency differences compared to the Erythrogene data.

Discussion

This study established blood group analysis methods using WGS data and analyzed the blood groups using Korean WGS public data. Blood group gene analysis differs from the genetic analysis used to diagnose tumors or congenital genetic diseases. There is a conventional reference allele for each blood group, and the SNPs and blood group genotypes according to the reference allele are well documented. There are several blood group gene databases. The Blood Group Antigen Mutation (BGMUT) Database was created by the Human Genome Variation Society (HGVS) in 1999 [14]. Since 2006, it has been operated by the National Institutes of Health (NIH) as part of the database Red Blood Cells (dbRBC) of the National Center for Biotechnology Information (NCBI), which ceased operation in October 2017. In 2016, Moller et al. created the Erythrogene database following analysis of 36 blood groups from the 1000 Genomes Project [9]. There are also the ISBT website [13], the Blood Group Antigen Facts-Book [18], and BOOGIE [19]. Since the blood group genotypes of hg19 are not the same as the conventional reference alleles of each blood group, we first analyzed the blood group genotypes of the human reference genome and noted the differences compared to the conventional reference alleles. Since most variant analysis software is designed to find variants by comparing the nucleotide sequences to the human reference genome, variant analysis is performed on blood group-related genes in the same way as other genetic analyses. Therefore, the results of variant detection alone cannot determine the blood group types. In this study, the differences between hg19 and conventional cDNA were analyzed first (Table 1), and we used these results to conduct blood group analyses in the WGS data. WGS data analysis, similar to other NGS data analyses, undergoes the same process of read mapping and variant detection after aligning

ISBT No.	System name (symbol)	Gene name	Nucleotide change	Predicted amino acid change	Allele name
001	ABO (ABO)	ABO	646T>A; 681G>A; 771C>T; 829G>A	Phe216Ile; Val277Met	ABO*AW.31.02- 05
002	MNS (MNS)	GYPA	-	-	ND
		GYPB	-	-	GYPB*04
003	P1PK (P1PK)	A4GALT	-	-	A4GALT*01
004	Rh (RH)	RHD	-	-	RHD* 10.00 RHD* DAU0
		RHCE	-	-	RHCE*01.01
005	Lutheran (LU)	BCAM	-	-	LU*02
006	Kell (KEL)	KEL	-	-	KEL*02
007	Lewis (LE)	FUT3	63A>G; 179G>A;189C>A; 201_202delACinsGT; 207A>G; 216_217delCCinsTA; 221_222delTCinsCA; 225T>C; 235T>C; 243T>C; 262A>G; 264A>G; 274C>A; 313_314delATinsGC; 344C>A; 351T>C; 353_355delAGTinsGTG; 366A>G; 407A>G; 409T>A; 415C>T; 417A>C; 421_423delCCTinsAGC; 431A>G; 451A>G; 732C>T; 1007A>C	Arg60His; Arg68Trp; His73Asn; Ile74Thr; Ser79Pro; Thr88Ala; His92Asn; Met105Ala; Ser115Tyr; Lys118_Ser119delinsSerAla; Asn136Ser; Leu137Met; Pro139Ser; Pro141Ser; Gln144Arg; Arg151Gly; Asp336Ala	ND
008	Duffy (FY)	ACKR1	-	-	FY*01
009	Kidd (JK)	SLC14A1	-	-	JK*01
010	Diego (DI)	SLC4A1	-	-	DI*02
011	Yt (YT)	ACHE	1790C>T; 1794G>C; 1796C>T; 1811A>T; 1814_1815delAGinsTC; 1818T>C; 1834_1835delTCinsCT; 1838A>T	Pro597Leu; Pro599Leu; His604Leu; Gln605Leu; His613Leu;	YT*01
012	Xg (XG)	XG	-	-	XG*01
013	Scianna (SC)	ERMAP	-	-	SC*01
014	Dombrock (DO)	ART4	-	-	DO*02
015	Colton (CO)	AQP1	-	-	CO*01.01
016	Landsteiner- Wiener (LW)	ICAM4	-	-	LW*05
017	Chido/Rodgers	C4A	-	-	C4A*3
	(CH/RG)	C4B	-	-	C4B*3
018	H (H)	FUT1	-	-	FUT1*01
		FUT2	-	-	FUT2*01
019	Kx (KX)	XK	-	-	XK*01
020	Gerbich (GE)	GYPC	-	-	GE*01
021	Cromer (CROM)	CD55	-	-	CROM*01
022	Knops (KN)	CR1	747A>G; 1843_1844delCCinsAT; 3281G>A; 3321T>C; 3354T>A; 3357C>T; 3562C>A; 3568T>C; 4828A>T; 4843A>G	Pro615Ile; Arg1094His; Asn1118Lys; Pro1188Thr; Thr1610Ser; Ile1615Val	KN*01
023	Indian (IN)	CD44	-	-	IN*02
024	Ok (OK)	BSG	-	-	OK*01.01
025	Raph (RAPH)	CD151	-	-	RAPH*01
026	John Milton Hagen (JMH)	SEMA7A	-	-	JMH*01
027	I (I)	GCNT2	576A>G; 601C>A; 606G>A; 616C>T; 816C>G; 856C>T; 864A>G; 870A>C; 873A>G; 876T>C; 882T>C; 912T>C; 919G>A; 922T>C	His206Tyr; Asp272Glu; Val307Ile; Ser308Pro	GCNT*01

Table 2. Prediction of various blood group systems in one representative data compared to conventional cDNA sequences analyzed using CLC Genomics Workbench.

(Continued)

ISBT No.	System name (symbol)	Gene name	Nucleotide change	Predicted amino acid change	Allele name
028	Globoside (GLOB)	B3GALNT1	131T>C; 136_138delCGCinsTAT; 141_142delGAinsAG; 156C>T; 159_160delTGinsCA; 391T>C; 434G>A; 526G>A; 528A>C; 589C>T; 675T>A; 838A>G; 890_891delTGinsCA; 904C>T; 906_907delGAinsTG; 910C>T	Ile44Thr; Arg46Tyr; Asn48Asp; Glu54Lys; Arg145Gln;Val176Ile; Asn280Asp; Leu297Ser; Arg303Gly; Arg304Cys	GLOB*01
029	Gill (GIL)	AQP3	-	-	GIL*01
030	Rh-associated glycoprotein (RHAG)	RHAG	-	-	RHAG*01
031	FORS (FORS)	GBGT1	728G>A	Arg243His	GBGT1*01N.01
032	JR (JR)	ABCG2	-	-	ABCG2*01
033	LAN (LAN)	ABCB6	117G>A	-	ABCB6*01
034	Vel (VEL)	SMIM1	-	-	VEL*01
035	CD59 (CD59)	CD59	-	-	CD59*01
036	Augustine (AUG)	SLC29A1	-	-	AUG*01
Associa	ted genes	GATA1	-	-	GATA1*01
Associa	ted genes	KLF1	304T>C	Ser102Pro	KLF1*BGM12

Table 2. (Continued)

ISBT, International Society of Blood Transfusion; ND, not determined

https://doi.org/10.1371/journal.pone.0269481.t002

the sequences to the human reference sequence. Then the alleles are analyzed alongside the phenotype of each blood group using the detected variants.

Alleles were successfully predicted in most blood groups except for ABO (*ABO*) and Lewis (*FUT3*), which were difficult to predict using WGS data alone. ABO and Lewis antigens are carbohydrate antigens synthesized by enzymes [20]. The A and B genes of the ABO blood group are alleles located in the same position; having a blood type A means having the phenotype of A, but even with the same phenotype, the genotype may be *AA* or *AO*. Over 200 genotypes have been reported for *ABO*, which include nucleotide changes in various regions. However, the vcf file obtained following variant detection cannot distinguish the two alleles. Moreover, because carbohydrate antigen prediction requires the evaluation of several related genes, and the alleles associated with carbohydrate antigens are complex [5], determination of alleles based only on WGS data is challenging, and support is needed to establish the phenotyping results. It was difficult to determine the blood type using only the WGS data for the Lewis blood group, for which factors other than *FUT2* and *FUT3* genes are involved in the blood group phenotype.

Additionally, none of the variants of the RH (*RHD* and *RHCE*) and MNS (*GYPA* and *GYPB*) blood system were detected in the Korean public WGS data. However, we visually confirmed that the mapping and variant detection of these genes were performed successfully. Although the data were not included in this study, we also conducted the blood group analysis using the WGS data from clinical samples, and more variants were detected. The public data used was obtained from the Human Resource Distribution Desk of the National Institute of Health of the KDCA. These data sets were collected through the Korean Reference Genome Project between 2012 and 2014 using HiSeq2000 (Illumina, San Diego, CA, USA) analysis with a maximum of 30× depth coverage per sample [21]. The BAM files were already aligned to hg19 and we used hg19 as the reference genome. We judged that insufficient variant data

Luberan BCAM - LU^02 10% 99.3% 84.82% 66.77% Kell 230G>A Arg7This LU'01 0% 0.10% 0.61% 0.022% Kell - KEL 0.00% 100% 65.37%* 65.37%* Daffy ACK1 - FK102 30% 89.5% 7.74% 20.51%* Daffy ACK1 - Aspt2Cly FV101 93.02% 91.05% 83.23%* 43.65%* Daffy ACK41 - - D102 100% 93.08% 7.85.7%* 83.85%* Diggo SLC4A1 - D102 100% 93.08% 7.85.7%* 83.85%* Diggo SLC4A1 - - D102 100% 93.08% 86.31%* 66.77%* Campoint AC 1.90C51 Pro854Leu D101 0% 93.08% 86.31%* 66.87%* Campoint ACG - XC'01 90.05% 0.22% <t< th=""><th>Blood group</th><th>Gene</th><th>Nucleotide changes</th><th>Predicted amino acid changes</th><th>Allele name</th><th>This study (205)</th><th>KRBP study (419)</th><th>Erythrogene (East Asia) (504)</th><th>Erythrogene (2,504)</th></t<>	Blood group	Gene	Nucleotide changes	Predicted amino acid changes	Allele name	This study (205)	KRBP study (419)	Erythrogene (East Asia) (504)	Erythrogene (2,504)
m 230G>A Arg77His LU*01 0% 0.61% 0% 0.22% Kell . . KEL'02 100% 6.51% 65.39% 65.39% Duffy ACKR1 . . FY'02 3.91% 8.95% 7.74% 20.51% Duffy ACKR1 . . . FY'02 3.91% 8.95% 7.74% 20.51% Duffy ACKR1 . . . 93.02% 91.05% 83.23% 43.65% Diego SLC4A1 . . DT'02 100% 93.02% 78.57% 83.85% 125A Asp42Giy Lea67Phe DT'02 100% 65.2% 0.30% 0.18% Y1 ACHE . . YT'01 100% 99.88% 86.31% 68.77% Xg XG . . XC'01 100% NA 99.75% 95.60% Scianna ERMAP . . SC'01 96.69% </td <td>Lutheran</td> <td>BCAM</td> <td>-</td> <td>-</td> <td>LU*02</td> <td>100%</td> <td>99.39%</td> <td>84.82%^c</td> <td>66.77%^c</td>	Lutheran	BCAM	-	-	LU*02	100%	99.39%	84.82% ^c	66.77% ^c
Kell Kell · Kell ·02 100% 100% 63.79%' 65.93%' Denfy KCR0 · F702 3.01% 8.95%' 7.74% 2.051%' Denfy ACKR1 · · F7'01 93.02% 91.05% 8.32.3%' 43.65%' Denfy 125A>G Asp42Gly F7'01 93.02% 91.05% 8.3.23%' 43.65%' Diego 125A>G Asp42Gly F7'01 93.02% NA 8.3.23%' 43.65%' Diego SLCIA1 · · DI'02 100% 93.08%' 7.8.57%' 83.85%' Y · · · DI'02 100% 69.25%' 0.00% 0.18%' Y · · · YT'01 100% 69.25%' 0.00% 0.26%' Sciana RAG · · SC'01 100% NA 9.9.87% 8.0.65.1%' Sciana SAG · SC'01 100%			230G>A	Arg77His	LU*01	0%	0.61%	0%	0.22%
Image: mark transform Thr 193Met $KEL^{\circ}0.01$ 0% 0% 0% $1.12\%^{\circ}$ Duffy $ACKR$ - - $F^{\circ}02$ 3.01% $8.95\%^{\circ}$ 7.74% $0.01\%^{\circ}$ Duffy $125\Lambda > G_{i}$ $Aspt2Gly: Leto?Phe$ $100G$ only $3.07\%^{\circ}$ NA $8.73\%^{\circ}$ $2.16\%^{\circ}$ Diego $SLCA1$ - $D^{\circ}OC$ $10\%^{\circ}$ $9.08\%^{\circ}$ $78.57\%^{\circ}$ $8.838\%^{\circ}$ Diego $SLCA1$ - $D^{\circ}OC$ $10\%^{\circ}$ $9.08\%^{\circ}$ $78.57\%^{\circ}$ $8.838\%^{\circ}$ Yl $ACHE$ - $Pro854Leu$ $D\Gamma'O$ $0\%^{\circ}$ $9.29.8\%^{\circ}$ $8.631\%^{\circ}$ $0.87\%^{\circ}$ Xg XG - $YT'OI$ $10\%^{\circ}$ $9.25\%^{\circ}$ $0.867\%^{\circ}$ $0.87\%^{\circ}$ $0.87\%^{\circ}$ Xg XG - $XC'OI$ $96.0\%^{\circ}$ $100\%^{\circ}$ $0.2\%^{\circ}$ $0.2\%^{\circ}$ $Sianna$ $ERMAP$ - $SC'OI$ $96.0\%^{\circ}$ $0.0\%^{\circ}$	Kell	KEL	-	-	KEL*02	100%	100%	63.79% ^c	65.93% ^c
Daffy $ACKRI$ $ FY 02$ 3.91% $8.95\%^2$ 7.74% $20.51\%^2$ I2SA-G Asp42Gly $FY 01$ 93.02% 91.05% $83.23\%^2$ $43.65\%^2$ Diego $SLC4AI$ $ D'' 02$ 100% $93.08\%^2$ $78.57\%^2$ $83.85\%^2$ Diego $SLC4AI$ $ D'' 02$ 100% $92.08\%^2$ $78.57\%^2$ $83.85\%^2$ Na $2561C>T$ Pro854Leu $D'' 01$ 100% $92.88\%^2$ 03.0% 0.18% Y1 $ACHE$ $ YT' 01$ 100% 99.88% $86.31\%^2$ $68.77\%^2$ Sciana $ERMAP$ $ SC' 01$ $95.60\%^2$ 02.0% $0.06\%^2$ 93.75% $81.07\%^2$ Sciana $ERMAP$ $ SC' 01$ $95.60\%^2$ $100\%^2$ $92.8\%^2$ $0.50\%^2$ $92.50\%^2$ Dombrock $ART4$ $ D'' 01$			578C>T	Thr193Met	KEL*01.01	0%	0%	0%	1.12% ^a
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	Duffy	ACKR1	-	-	FY*02	3.91%	8.95% ^a	7.74%	20.51% ^c
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$			125A>G	Asp42Gly	FY*01	93.02%	91.05%	83.23% ^c	43.65% ^c
Diego SLC4A1 - Df 02 100% 93.08% ^c 78.57% ^c 83.85% ^c V1 2561C>T Pro854Leu Df 01 0% 6.92% ^c 0.00% 0.18% Y1 ACHE - - YT ^o 01 10% 9.88% 86.31% ^c 68.77% ^c X2 M 1057C>A His353An YT ^o 01 100% NA 99.87% 86.31% ^c 68.77% ^c Xg XG - XG'01 100% NA 99.87% 95.60% ^b Scianna ERMAP - . XG'01 90.0% NA 99.87% 81.07% ^c Scianna ERMAP - . SC'01 96.0% 00% 0% 0.06% 1248C>T 11248C>T 1000G only 0.28% NA 1.19% 0.66% ^c Dombrock AR74 - . D'0'01 3.35% NA 1.79% 0.66% ^c Colton AQ1 - . D'0'			125A>G; 199C>T	Asp42Gly; Leu67Phe	1000G only	3.07%	NA	8.73% ^b	2.16%
Image: mark mark mark mark mark mark mark mark	Diego	SLC4A1	-	-	DI*02	100%	93.08% ^c	78.57% ^c	83.85% ^c
Yt $ACHE$ - YT 01 100% 99.88% 86.31% ^c 68.77% ^c M 1057C>A His353Asn YT 02 0% 0.12% 0.20% 2.46% ^c Xg XG - XG '01 100% NA 99.87% 95.60% ^b Sciana ERMAP - - SC '01 96.09% 100% ^c 93.75% 81.07% ^c Sciana ERMAP - SC '01 96.09% 100% ^c 93.75% 81.07% ^c 169G>A Gly57Arg SC '02 0.28% 0% 0% 0.06% ^c 1248C>T Val279Ile 1000G only 0.28% NA 1.19% 0.26% Dombrock AR74 - - DO'01 3.35% NA 1.99% 25.10% ^c Colton AQP1 - - DO'02 96.37% 89.86% ^b 82.54% ^c 59.37% ^c Colton AQP1 - - CO'01.01 100% NA 99.0			2561C>T	Pro854Leu	DI*01	0%	6.92% ^c	0.30%	0.18%
Image: system of the	Yt	ACHE	-	-	YT*01	100%	99.88%	86.31% ^c	68.77% ^c
Xg XG - XG^{\circ}01 100% NA 99.87% 95.60% ^b Sciana ERMAP - SC*01 96.09% 100% ^c 93.75% 81.07% ^c Sciana ERMAP - SC*01 96.09% 100% ^c 93.75% 81.07% ^c Na 169G>A Gly57Arg SC*02 0.28% 0% 0% 0.06% Na 1248C>T Val290le 1000G only 3.35% NA 1.19% 0.26% Dombrock ART4 - - DO'01 3.35% NA 1.79% 0.66% ^c Dombrock ART4 - - DO'02 96.37% 89.86% ^b 82.54% ^c 59.37% ^c Colton AQP1 - CO'01.01 100% NA 99.01% 95.61% ^b Landsteiner- ICAM4 - - CO'01.01 100% NA 30.26% ^c 30.93% ^c Chid/Rogers C4A - - CH3'3 100%<			1057C>A	His353Asn	YT*02	0%	0.12%	0.20%	2.46% ^c
Sciana $ERMAP$ - SC '01 96.09% 100% ^c 93.75% 81.07% ^c Image: Sciana Inf9G>A Gly57Arg SC '02 0.28% 0% 0% 0.06% Image: Sciana 835G>A; 1248C>T Val279Ile 1000G only 0.28% NA 1.19% 0.26% Image: Sciana 976A>G Asn326Asp 1000G only 3.35% NA 1.79% 0.66% ^c Dombrock AR74 - - DO'01 3.35% NA 1.79% 0.66% ^c Dombrock AR74 - - DO'01 3.35% NA 1.79% 0.66% ^c Colton AQP1 - - CO'01.01 100% NA 99.1% 95.61% ^b Landsteiner- IfAAC>T Ala45Val CO'02 0% NA 99.1% 95.61% ^b Landsteiner- IfAAB - - CHA*3 100% NA 30.26% ^c 30.93% ^c Chido/Rogers C4A <t< td=""><td>Xg</td><td>XG</td><td>-</td><td>-</td><td>XG*01</td><td>100%</td><td>NA</td><td>99.87%</td><td>95.60%^b</td></t<>	Xg	XG	-	-	XG*01	100%	NA	99.87%	95.60% ^b
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	Scianna	ERMAP	-	-	SC*01	96.09%	100% ^c	93.75%	81.07% ^c
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$			169G>A	Gly57Arg	SC*02	0.28%	0%	0%	0.06%
Image: constraint of the second state of the seco			835G>A; 1248C>T	Val279Ile	1000G only	0.28%	NA	1.19%	0.26%
Dombrock $AR74$ $ DO^{\circ}01$ 3.35% $10.14\%^{b}$ $9.42\%^{b}$ $25.10\%^{c}$ $Colon$ $AQP1$ $ 793A>G$ $Asn265Asp$ $DO^{\circ}02$ 96.37% $89.86\%^{b}$ $82.54\%^{c}$ $59.37\%^{c}$ $Colton$ $AQP1$ $ CO^{\circ}01.01$ 100% NA 99.01% $95.61\%^{b}$ $Colton$ $AQP1$ $ CO^{\circ}02$ 0% NA 0% $1.14\%^{a}$ $Landsteiner-WienerICAM4 LW^{*}05100\%100\%99.70\%98.96\%Chido/RogersC4A C4A^{*}3100\%NA30.26\%^{c}30.93\%^{c}Chido/RogersC4A C4A^{*}3100\%NA30.26\%^{c}30.93\%^{c}HFUT1 C4B^{*}3100\%NA30.26\%^{c}30.93\%^{c}HFUT1 C4B^{*}3100\%NA99.40\%99.50\%KxXK C4B^{*}3100\%NA99.40\%99.50\%KxXK FUT1^{*}027.82\%NA31.25\%^{c}9.82\%KxXK XK^{*}01100\%NA99.50\%97.40\%^{a}GromerCD55 CROM^{*}01100\%NA99.60\%97.72\%^{a}IndianCD44$			976A>G	Asn326Asp	1000G only	3.35%	NA	1.79%	0.66% ^c
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	Dombrock	ART4	-	-	DO*01	3.35%	10.14% ^b	9.42% ^b	25.10% ^c
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $			793A>G	Asn265Asp	DO*02	96.37%	89.86% ^b	82.54% ^c	59.37% ^c
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	Colton	AQP1	-	-	CO*01.01	100%	NA	99.01%	95.61% ^b
Landsteiner- Wiener $ICAM4$ LW^*05 100% 100% 99.70% 98.96% Chido/Rogers $C4A$ $C4A^*3$ 100% NA $30.26\%^c$ $30.93\%^c$ Chido/Rogers $C4B$ $C4B^*3$ 100% NA 99.40% 99.50% H $FUT1$ $C4B^*3$ 100% NA 99.40% 99.50% H $FUT1$ $FUT1^*01$ 91.62% NA $67.66\%^c$ $89.22\%^c$ Max XK Kx^*01 100% NA 100% 99.50% Kx XK XK^*01 100% NA 99.50% $97.40\%^a$ Gerbich $GYPC$ GE^*01 100% NA 99.50% $97.20\%^a$ Indian $CD44$ $CROM^*01$ 100% NA 99.60% $97.72\%^a$ Indian $CD44$ $CROM^*01$ 100% NA 99.80% 99.04% Ok BSG $OK^*01.01$ 100% NA 99.80% 99.04% Iphn Milton $SEMA7A$ $RAPH^*01$ 100% NA 99.11% $96.37\%^b$			134C>T	Ala45Val	CO*02	0%	NA	0%	1.14% ^a
Chido/Rogers $C4A$ $C4A^*3$ 100% NA $30.26\%^c$ $30.93\%^c$ $C4B$ $C4B^*3$ 100% NA 99.40% 99.50% H $FUT1$ $FUT1^*01$ 91.62% NA $67.66\%^c$ $89.22\%^c$ T $35C>T$ $Ala12Val$ $FUT1^*02$ 7.82% NA $31.25\%^c$ 9.82% Kx XK XK^*01 100% NA 100% 99.50% Gerbich $GYPC$ GE^*01 100% NA 99.50% $97.40\%^a$ Cromer $CD55$ $CROM^*01$ 100% NA 99.60% $97.72\%^a$ Indian $CD44$ IN^*02 100% NA 99.80% 99.04% Ok BSG $OK^*01.01$ 100% NA 99.81% 98.20% Iphn Milton $SEMA7A$ IM^*01 100% NA 99.11% $96.37\%^b$	Landsteiner- Wiener	ICAM4	-	-	LW*05	100%	100%	99.70%	98.96%
$C4B$ $C4B^*3$ 100%NA99.40%99.50%H $FUT1$ $FUT1^*01$ 91.62%NA $67.66\%^c$ $89.22\%^c$ M $35C>T$ Ala12Val $FUT1^*02$ 7.82% NA $31.25\%^c$ 9.82% KxXK XK^*01 100% NA 100% 99.92% Gerbich $GYPC$ GE^*01 100% NA 99.50% $97.40\%^a$ Cromer $CD55$ $CROM^*01$ 100% NA 99.60% $97.72\%^a$ Indian $CD44$ IN^*02 100% NA 99.80% 99.04% Ok BSG $OK^*01.01$ 100% NA 98.91% 98.94% John Milton $SEMA7A$ IMH^*01 100% NA 99.11% $96.37\%^b$	Chido/Rogers	C4A	-	-	C4A*3	100%	NA	30.26% ^c	30.93% ^c
H FUT1 - - FUT1*01 91.62% NA 67.66% ^c 89.22% ^c M 35C>T Ala12Val FUT1*02 7.82% NA 31.25% ^c 9.82% Kx XK - - XK*01 100% NA 100% 99.92% Gerbich GYPC - - XK*01 100% NA 99.50% 97.40% ^a Cromer CD55 - - CROM*01 100% NA 99.60% 97.72% ^a Indian CD44 - - IN*02 100% NA 99.80% 99.04% Ok BSG - - OK*01.01 100% NA 97.62% ^a 98.20% Raph CD151 - - RAPH*01 100% NA 98.91% 98.94% John Milton SEMA7A - - JMH*01 100% NA 99.11% 96.37% ^b		C4B	-	-	C4B*3	100%	NA	99.40%	99.50%
Image: constraint of the system $35C>T$ Ala12Val $FUT1^*02$ 7.82% NA $31.25\%^c$ 9.82% KxXK XK^*01 100% NA 100% 99.92% GerbichGYPC GE^*01 100% NA 99.50% $97.40\%^a$ CromerCD55CROM*01 100% 100% 99.60% $97.72\%^a$ IndianCD44IN*02 100% NA 99.80% 99.04% OkBSG $OK^*01.01$ 100% NA $97.62\%^a$ 98.20% Iphn MiltonSEMA7AIMH*01 100% NA 99.11% $96.37\%^b$	Н	FUT1	-	-	FUT1*01	91.62%	NA	67.66% ^c	89.22% ^c
Kx XK - - XK*01 100% NA 100% 99.92% Gerbich $GYPC$ - - $GE*01$ 100% NA 99.50% 97.40% ^a Cromer $CD55$ - - $CROM*01$ 100% 100% 99.60% 97.72% ^a Indian $CD44$ - - $IN*02$ 100% NA 99.80% 99.04% Ok BSG - - $OK*01.01$ 100% NA 97.62% ^a 98.20% Raph $CD151$ - - $RAPH*01$ 100% NA 98.91% 98.94% John Milton $SEMA7A$ - - $JMH*01$ 100% NA 99.11% 96.37% ^b			35C>T	Ala12Val	FUT1*02	7.82%	NA	31.25% ^c	9.82%
Gerbich $GYPC$ - - GE^*01 100% NA 99.50% $97.40\%^a$ Cromer $CD55$ - - $CROM^*01$ 100% 100% 99.60% $97.72\%^a$ Indian $CD44$ - - IN^*02 100% NA 99.80% 99.04% Ok BSG - - $OK^*01.01$ 100% NA 99.80% 99.04% Ok BSG - - $OK^*01.01$ 100% NA 99.80% 99.20% Ohn Milton $SEMA7A$ - - $RAPH^*01$ 100% NA 99.11% $96.37\%^b$	Kx	XK	-	-	XK*01	100%	NA	100%	99.92%
Cromer CD55 - - CROM*01 100% 100% 99.60% 97.72% ^a Indian CD44 - - IN*02 100% NA 99.80% 99.04% Ok BSG - - OK*01.01 100% NA 97.72% ^a Raph CD151 - - OK*01.01 100% NA 97.62% ^a 98.20% John Milton SEMA7A - - RAPH*01 100% NA 98.91% 98.94%	Gerbich	GYPC	-	-	GE*01	100%	NA	99.50%	97.40% ^a
Indian CD44 - - IN*02 100% NA 99.80% 99.04% Ok BSG - - OK*01.01 100% NA 97.62% ^a 98.20% Raph CD151 - - RAPH*01 100% NA 98.91% 98.94% John Milton SEMA7A - - JMH*01 100% NA 99.11% 96.37% ^b	Cromer	CD55	-	-	CROM*01	100%	100%	99.60%	97.72% ^a
Ok BSG - - OK*01.01 100% NA 97.62% ^a 98.20% Raph CD151 - - RAPH*01 100% NA 98.91% 98.94% John Milton SEMA7A - - JMH*01 100% NA 99.11% 96.37% ^b	Indian	CD44	-	-	IN*02	100%	NA	99.80%	99.04%
Raph CD151 - - RAPH*01 100% NA 98.91% 98.94% John Milton SEMA7A - - JMH*01 100% NA 99.11% 96.37% ^b	Ok	BSG	-	-	OK*01.01	100%	NA	97.62% ^a	98.20%
John Milton SEMA7A JMH*01 100% NA 99.11% 96.37% ^b	Raph	CD151	-	-	RAPH*01	100%	NA	98.91%	98.94%
nagen la	John Milton Hagen	SEMA7A	-	-	JMH*01	100%	NA	99.11%	96.37% ^b
FORS GBGT1 GBGT1*01N.01 94.14% NA 45.44% ^c 59.96% ^c	FORS	GBGT1	-	-	GBGT1*01N.01	94.14%	NA	45.44% ^c	59.96% ^c
397G>A Glu133Lys 1000G only 1.95% NA 0.20% ^c 0.04% ^c			397G>A	Glu133Lys	1000G only	1.95%	NA	0.20% ^c	0.04% ^c
707G>A Arg236His 1000G only 2.93% NA 0.50% ^c 0.12% ^c			707G>A	Arg236His	1000G only	2.93%	NA	0.50% ^c	0.12% ^c
728G>A Arg243His 1000G only 0.98% NA 0.30% 0.10% ^b			728G>A	Arg243His	1000G only	0.98%	NA	0.30%	0.10% ^b
JR ABCG2 34G>A Vall2Met 1000G only 2.44% NA 29.66% ^c 13.68% ^c	JR	ABCG2	34G>A	Val12Met	1000G only	2.44%	NA	29.66% ^c	13.68% ^c
167G>A Arg56Gln 1000G only 0.49% NA 0% 0.02% ^a	<u>-</u>		167G>A	Arg56Gln	1000G only	0.49%	NA	0%	0.02% ^a
Vel SMIM1 - - VEL*01 100% NA 99.90% 99.96%	Vel	SMIM1	-	-	VEL*01	100%	NA	99.90%	99.96%
Associated genes KLF1 KLF*01 73.66% NA 30.75% ^c 53.53% ^c	Associated genes	KLF1	_	-	KLF*01	73.66%	NA	30.75% ^c	53.53% ^c
304T>C Ser102Pro KF1*BGM12 22.93% NA 59.23% 37.88% ^c			304T>C	Ser102Pro	KF1*BGM12	22.93%	NA	59.23% ^c	37.88% ^c
325C>T Pro109Ser 1000G only 1.95% NA 7.64% ^c 1.54%			325C>T	Pro109Ser	1000G only	1.95%	NA	7.64% ^c	1.54%

Table 3. Comparison of allele frequencies between this study, KRBP and Erythrogene data.

(Continued)

Table 3. (Continued)

Blood group	Gene	Nucleotide	Predicted amino acid	Allele name	This study	KRBP study	Erythrogene (East	Erythrogene
		changes	changes		(205)	(419)	Asia) (504)	(2,504)
		304T>C; 544T>C	Ser102Pro; Phe182Leu	1000G only	0.98%	NA	1.69%	4.89% ^c

KRBP, Korean rare blood program; NA, not available

^aP value <0.05 between this study compared to KRBP, Erythrogene (East Asia), or Erythrogene

^bP value <0.01 between this study compared to KRBP, Erythrogene (East Asia), or Erythrogene

^cP value <0.001 between this study compared to KRBP, Erythrogene (East Asia), or Erythrogene

https://doi.org/10.1371/journal.pone.0269481.t003

was detected due to the lower coverage and poorer data quality compared to the clinical patient samples. High numbers of variants were detected in the *ACHE* (Yt), *CR1* (Knops), *GCNT2* (I), and *B3GALNT1*(Globoside) genes. However, it is not known whether most of these nucleotide changes encode antigenic epitopes [13], and we were able to predict the alleles in most cases (Table 2).



Fig 1. Comparison analysis of allele frequencies between this study, KRBP and Erythrogene data. Allele frequencies of Lutheran, Kell, Duffy (FY^*01), Yt, Landsteiner-Wiener, and Cromer blood group systems showed no significant differences between this study and KRBP study. However, the allele frequencies of Lutheran, Kell, Duffy (FY^*01), and Yt blood group systems showed significant differences from the Erythogene (East Asian and all races) data and allele frequency of Cromer blood group system showed significant difference from the Erythrogene (all races). The high-frequency alleles LU^*02 , KEL^*02 , FY^*01 , YT^*01 , SC^*01 , DO^*02 , and $CROM^*01$ were more frequent in Koreans than in East Asians or all races in the Erythrogene database. ^aP value <0.05 between this study compared to KRBP, Erythrogene (East Asia), or Erythrogene; ^bP value <0.01 between this study compared to KRBP, Korean rare blood program.

https://doi.org/10.1371/journal.pone.0269481.g001

We also investigated the frequencies of the major alleles and compared them to the frequencies of the KRBP and Erythrogene (East Asian and all races) data from the 1000 Genomes Project (Table 3). The 1000 Genomes Project contains data from 2,504 people from 26 races, divided into African (661), American (347), East Asian (504), European (503), and South Asian (489); however, the East Asians only include Chinese, Japanese, and Vietnamese people, but not Koreans [9]. Although it is well known that allele frequencies vary among ethnic groups, few studies exist on the allele frequencies in different blood group systems [10, 22]. Allele frequencies of Lutheran, Kell, Duffy, Diego, Yt, Scianna, Dombrock, Landsteiner-Wiener, and Cromer blood group systems were available in the KRBP data and Lutheran, Kell, Duffy (FY^*01) , Yt, Landsteiner-Wiener, and Cromer blood group systems showed no significant differences between this study and KRBP study in allele frequencies. However, the allele frequencies of Lutheran, Kell, Duffy (FY^*01) , and Yt blood group systems showed significant differences from the Erythogene (East Asian and all races) data and allele frequency of Cromer blood group system showed significant difference from the Erythrogene (all races). The highfrequency alleles LU*02, KEL*02, FY*01, YT*01, SC*01, DO*02, and CROM*01 were more frequent in Koreans than in East Asians or all races in the Erythrogene database. In the Duffy system, the allele frequency of FY*02 showed significant difference from the KRBP data (P = 0.023), but this was because the allele with 125A>G and 199C>T nucleotide changes was detected as the FY^*02 allele in the KRBP study. In the Diego system, the prevalence of the Di^a antigen is extremely rare in people of European or African descent, but is about 5% in people of Chinese or Japanese ancestry and has an even higher prevalence in the indigenous peoples of North and South America, reaching 54% [20]. The antigen prevalence of Di^a is 6.4–14.5% in Koreans [23]. The allele frequency of *DI**01 was 6.92% in the KRBP data, 0.30% in the East Asian Erythrogene data, and 0.18% in all the Erythrogene data. However, no DI*01 variants were detected in the Korean public WGS data. This could be due to the smaller sample size or poor quality of the WGS data. In the Dombrock system, the frequency of the DO*01 allele is lower in this study than in the KRBP study because the hg19 itself is DO^*02 , so the variant may not have been detected due to the low data quality. Numerous minor blood group systems that were not included in the KRBP data are included in our study. Antibodies to many of these antigens are rarely encountered because they are high-prevalence antigens in most populations; however, the Colton, Gerbich, RHAG, JR, LAN, and Vel systems can cause acute hemolytic transfusion reactions or hemolytic diseases in newborns [24, 25]. Accurate data on the frequencies of various blood group antigens are essential to predict the availability of compatible blood components for use in patients with the corresponding antibodies and are indispensable for rare blood program. Accurate information on the frequencies of specific antigennegative blood units will help reduce unnecessary antigen testing and avoid delays in issuing blood units to patients. Furthermore, it will contribute to improving blood transfusion safety and better blood supply management.

Conclusion

We successfully established blood group analysis methods using WGS data and performed blood group analyses on Korean public WGS data. There were some limitations in this study in terms of the number and quality of the WGS data sets. Also, additional tests such as serologic tests or further molecular assays could not be performed. Nevertheless, even using WGS or whole-exome sequencing (WES) data, which is not intended for blood group genotyping, we were able to analyze the various blood group alleles using the method established in this study. In addition, accumulating frequency data for diverse blood group systems will enable safe blood products and the provision of adequate blood supplies for patients with the relevant antibodies.

Supporting information

S1 Table. The source of the conventional reference alleles for the 41 blood group genes. (DOCX)

S1 Fig. Graphic work flow of this study. Part 1: Conventional reference alleles and coding DNA sequences (CDS) were investigated for 41 genes, including 39 blood group genes involved in 36 blood group antigens, and the GATA1 and KLF1 genes, which are erythrocytespecific transcription factor genes(12). The human reference genome (hg19) UCSC genomic transcripts (corresponding to the splicing pattern of the conventional CDS) for these 41 genes were also investigated using the UCSC genome browser(15). The CDS of the conventional reference alleles and the human reference genomes for each gene were aligned, and the Clustal Omega website was used to identify nucleotide changes(16).We then analyzed the differences between hg19 and conventional reference cDNA and determined the blood group alleles of hg19. Part 2: After importing the 250 Korean WGS data (BAM) using CLC genomic Workbench 11.0 (Qiagen, Aarhus, Denmark)(17), the data were realigned to hg19, and variant analysis was performed on the coding regions of the 41 blood group-related genes. The alleles of each blood group were predicted by analyzing the variants for each gene and comparing them with the hg19 genotype. Abbreviations: CDS, coding DNA sequences; WGS, whole-genome sequencing. (TIF)

S1 File. The variant analysis file of 250 data. (XLSX)

Acknowledgments

This study was conducted with bioresources from National Biobank of Korea, the Korea Disease Control and Prevention Agency, Republic of Korea (2018–013).

Author Contributions

Conceptualization: Jungwon Hyun, Kyoung Un Park.

Data curation: Jungwon Hyun.

Investigation: Jungwon Hyun.

Methodology: Jungwon Hyun.

Project administration: Yun Ji Hong, Kyoung Un Park.

Supervision: Kyoung Un Park.

Validation: Jungwon Hyun, Sujin Oh, Yun Ji Hong.

Writing - original draft: Jungwon Hyun.

Writing - review & editing: Sujin Oh, Yun Ji Hong, Kyoung Un Park.

References

- 1. ISBT. Red Cell Immunogenetics and Blood Group Terminology. [updated 2021 Jun 30. Available from: https://www.isbtweb.org/working-parties/red-cell-immunogenetics-and-blood-group-terminology.
- Liu Z, Liu M, Mercado T, Illoh O, Davey R. Extended blood group molecular typing and next-generation sequencing. Transfus Med Rev. 2014; 28(4):177–86. https://doi.org/10.1016/j.tmrv.2014.08.003 PMID: 25280589

- Quill E. Medicine Blood-matching goes genetic. Science. 2008; 319(5869):1478–9. <u>https://doi.org/10.1126/science.319.5869.1478 PMID: 18339916</u>
- Schoeman EM, Lopez GH, McGowan EC, Millard GM, O'Brien H, Roulis EV, et al. Evaluation of targeted exome sequencing for 28 protein-based blood group systems, including the homologous gene systems, for blood group genotyping. Transfusion. 2017; 57(4):1078–88. <u>https://doi.org/10.1111/trf.</u> 14054 PMID: 28338218
- Lane WJ, Westhoff CM, Uy JM, Aguad M, Smeland-Wagman R, Kaufman RM, et al. Comprehensive red blood cell and platelet antigen prediction from whole genome sequencing: proof of principle. Transfusion. 2016; 56(3):743–54. https://doi.org/10.1111/trf.13416 PMID: 26634332
- Fichou Y, Audrezet MP, Gueguen P, Le Marechal C, Ferec C. Next-generation sequencing is a credible strategy for blood group genotyping. Br J Haematol. 2014; 167(4):554–62. <u>https://doi.org/10.1111/bjh.</u> 13084 PMID: 25135605
- Rieneck K, Bak M, Jonson L, Clausen FB, Krog GR, Tommerup N, et al. Next-generation sequencing: proof of concept for antenatal prediction of the fetal Kell blood group phenotype from cell-free fetal DNA in maternal plasma. Transfusion. 2013; 53(11 Suppl 2):2892–8. https://doi.org/10.1111/trf.12172 PMID: 23550721
- Stabentheiner S, Danzer M, Niklas N, Atzmuller S, Proll J, Hackl C, et al. Overcoming methodical limits of standard RHD genotyping by next-generation sequencing. Vox Sang. 2011; 100(4):381–8. https:// doi.org/10.1111/j.1423-0410.2010.01444.x PMID: 21133932
- Moller M, Joud M, Storry JR, Olsson ML. Erythrogene: a database for in-depth analysis of the extensive variation in 36 blood group systems in the 1000 Genomes Project. Blood Adv. 2016; 1(3):240–9. https://doi.org/10.1182/bloodadvances.2016001867 PMID: 29296939
- Hong YJ, Chung Y, Hwang SM, Park JS, Kwon JR, Choi YS, et al. Genotyping of 22 blood group antigen polymorphisms and establishing a national recipient registry in the Korean population. Ann Hematol. 2016; 95(6):985–91. https://doi.org/10.1007/s00277-016-2645-7 PMID: 27021300
- Shin DW, Kim H, Chung Y, Kim JN, Hong YJ, Park KU, et al. Establishment and Utilization of a Transfusion Recipient Registry in Korea: Estimating the Frequencies of Specific Antigen-Negative Blood Units. Am J Clin Pathol. 2018; 150(2):154–61. https://doi.org/10.1093/ajcp/agy044 PMID: 29893771
- 12. Erythrogene. The search engine for blood group genes [updated 2017, November 27. Available from: http://www.erythrogene.com/.
- 13. ISBT. Blood Group Allele Tables. [Available from: https://www.isbtweb.org/working-parties/red-cellimmunogenetics-and-blood-group-terminology.
- Patnaik SK, Helmberg W, Blumenfeld OO. BGMUT Database of Allelic Variants of Genes Encoding Human Blood Group Antigens. Transfus Med Hemother. 2014; 41(5):346–51. <u>https://doi.org/10.1159/ 000366108</u> PMID: 25538536
- 15. Institute UoCSCG. UCSC Genome Browser [Available from: https://genome.ucsc.edu/.
- 16. EMBL-EBI. Clustal Omega 2021 [Available from: https://www.ebi.ac.uk/Tools/msa/clustalo/.
- QIAGEN. CLC Genomics Workbench [Available from: https://www.qiagen.com/us/products/discoveryand-translational-research/next-generation-sequencing/informatics-and-data/analysis-andvisualization/clc-genomics-workbench/.
- Reid ME, Lomas-Francis C, Olsson ML. The blood group antigen factsbook. Third edition. ed. Amsterdam: Elsevier/AP; 2012. xii, 745 pages p.
- Giollo M, Minervini G, Scalzotto M, Leonardi E, Ferrari C, Tosatto SC. BOOGIE: Predicting Blood Groups from High Throughput Sequencing Data. PLoS One. 2015; 10(4):e0124579. https://doi.org/10. 1371/journal.pone.0124579 PMID: 25893845
- Cohn CS DM, Johnson ST, Katz LM. Technical manual. 20th ed. Bethesda: American Association of Blood Banks; 2020.
- Jeong G CS. Introduction to the Korean Reference Genome Database (KRGDB) [Available from: https://yesme.kiom.re.kr/Trend/articles/do_print/tableid/tech/page/7/view_type/webzine/id/1392.
- Shin KH, Lee HJ, Kim HH, Hong YJ, Park KU, Kim MJ, et al. Frequency of Red Blood Cell Antigens According to Parent Ethnicity in Korea Using Molecular Typing. Ann Lab Med. 2018; 38(6):599–603. https://doi.org/10.3343/alm.2018.38.6.599 PMID: 30027705
- 23. Han KS PK, Song EY. Transfusion Medicine. 4th ed. Seoul: Korea Medical Book Publisher; 2014. 224–5 p.
- 24. Moghaddam M, Naghi AA. Clinical significance of antibodies to antigens in the Raph, John Milton Hagen, I, Globoside, Gill, Rh-associated glycoprotein, FORS, JR, LAN, Vel, CD59, and Augustine blood group systems. Immunohematology. 2018; 34(3):85–90. PMID: 30295501

 Crottet SL. Clinical significance of antibodies to antigens in the Scianna, Dombrock, Colton, Landsteiner-Weiner, Chido/Rodgers, H, Kx, Cromer, Gerbich, Knops, Indian, and Ok blood group systems. Immunohematology. 2018; 34(3):103–8. PMID: <u>30295505</u>